Risk Factors Update Summary
- Recently approved ex vivo CRISPR-based therapy in the U.S. and EU. This approval is significant.
- Increase in ownership percentage from 30% to 38% by executive officers, directors, and affiliates.
- The analysis now covers until December 31, 2022, potentially impacting tax attributes.
- Issued 518,889 shares of common stock at an average price of $37.80, raising $19.6 million.
- A change in control during 2023 could limit tax attributes, affecting financials.
- Raised $70.9 million through the sale of 2,200,000 shares at $32.42 per share.
- Ownership changes may impact the utilization of NOLs and tax attributes.
- Increased federal and state NOLs from $852 million to $954 million and $797 million to $922.8 million, respectively.
- Federal and state research and development credit carryforwards increased from $63 million to $100 million and $48 million to $64 million, respectively.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1652130&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.